Navigation Links
Prometheus Licenses COLAL-PRED(R) From Alizyme
Date:11/29/2007

cautions that any forward-looking information is not a guarantee of future performance. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Prometheus' business, including risks related to COLAL-PRED and the license agreement with Alizyme (including, without limitation, Prometheus' ability to develop the licensed products, or complete any required clinical trials, Prometheus' ability to obtain required regulatory approvals of the licensed products, adverse side effects or inadequate therapeutic efficacy of COLAL-PRED and any resulting product liability claims, the potential market for the drug delivery technology, and the potential for termination of the license agreement). There can be no assurance that Prometheus can successfully commercialize or penetrate the market for the licensed products.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
5. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
6. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
7. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
8. Syngenta Licenses Chromatin Gene Stacking Technology
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... (PRWEB) , ... August 26, 2015 , ... ... Solutions, announces today that a second US laboratory is to open in Manhattan, ... with the continued partnership and long-term growth of research and development through collaboration ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
(Date:8/26/2015)... SPRINGS, Florida , August 26, 2015 /PRNewswire/ ... of the biggest factors fueling the optimism in ... approvals, M&A,s, collaborations and life sciences advancements.  Active ... developments are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, ... (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. recently ... The company has added a AS16 Sharples centrifuge to harvest products after fermentation. ... or fungal fermentation process development. , The new centrifuge greatly expands production ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... and macromolecular science at Case Western Reserve University, and ... optical imaging of anisotropic fluids such as liquid crystals, ... techniques. A research paper detailing the team,s findings appeared ... . , The molecules of these fluids, such as ...
... Guidance to $245 Million to $247 Million -, Third Quarter 2008 Highlights:, ... third quarter of 2007 -- Total revenues without Osteocel of $62.5 ... 2007, -- Gross profit of $54.7 million; up 73.2% from ... compared to 82.0% in the third quarter of 2007, -- ...
... Dynamic Alert Limited,(OTC Bulletin Board: DYMC) (the "Company") ... of medical cannabis-based,pharmaceutical products. Today the Company is ... acquire all of the assets of Cannex, a ... and political,activist Steven W. Kubby (http://www.kubby.com ). ...
Cached Biology Technology:Case Western Reserve University researcher improves LCDs with 3-D nanoimaging process 2Case Western Reserve University researcher improves LCDs with 3-D nanoimaging process 3Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 2Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 3
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... plots in the Northeast and Midwestern United States contain at ... study found. The study across two dozen states from North ... the landscape where invasive plants might take root. "We ... forest inventory had at least one introduced species, but this ...
... related in composition to the active ingredient in marijuana may ... the Journal of Leukocyte Biology shows ... in white blood cells, specifically macrophages, appear to weaken HIV-1 ... which the pharmaceutical properties of cannabis are manifested. Diminishing ...
... the remains of a recent lottery winner having been exhumed ... wonder what they can do to avoid the same fate. ... involving zebrafish suggests that riboflavin, also known as vitamin ... In addition, the report shows that zebrafish are a viable ...
Cached Biology News:In the Northeast, forests with entirely native flora are not the norm 2Synthetic derivatives of THC may weaken HIV-1 infection to enhance antiviral therapies 2Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning 2
See product name for description....
... excluding l-[U-14C]methionine, 1.85 MBq, 50 uCi. ... > 1.85 GBq/mg atom carbon, ... Mixture of Ala, Arg, Asp, Glu, ... Pro, Ser, Thr, Tyr and Val.1.85 ...
Request Info...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Biology Products: